Navigation Links
Spectral announces presentations at the 29TH International Symposium on Intensive Care and Emergency Medicine focusing on the role of endotoxin
Date:3/25/2009

TORONTO, March 25 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc. (TSX:SDI), a company developing products for the treatment of sepsis, today announced that the 29th International Symposium on Intensive Care and Emergency Medicine in Brussels, Belgium from March 24-27, 2009 will feature a key scientific symposium entitled, "The Role of Endotoxin", that will include presentations from six thought leaders in the field of sepsis. Presentations will include topics such as defining the role that endotoxin plays in sepsis and organ dysfunction; using Spectral's Endotoxin Activity Assay (EAA(TM)) to determine optimum management of patients with intra-abdominal infections; and, the role of diagnosing and treating endotoxemia in patients with severe sepsis and septic shock.

"The prominence given to endotoxin at this significant international conference reflects the increased recognition within the critical care community of its role in sepsis," said Dr. Paul Walker, President and CEO of Spectral Diagnostics. "Results presented at this conference highlight the efficacy of our EAA(TM) in identifying patients most likely to benefit from anti-endotoxin therapies and the effectiveness of the Toraymyxin(TM) product to remove endotoxin and improve patient outcomes."

Spectral recently acquired the rights to Toraymyxin(TM) for the United States, where there is a significant unmet need for the approximately 100,000 patients that develop severe sepsis or septic shock each year. Additional information on the 29th International Symposium on Intensive Care and Emergency Medicine can be found at www.intensive.org.

About Spectral Diagnostics

Spectral is a leader in the battle against sepsis. Spectral's lead product is its Endotoxin Activity Assay (EAA(TM)), the only FDA cleared assay for the measurement of endotoxin. With the growing awareness for the role of endotoxemia in sepsi
'/>"/>

SOURCE Spectral Diagnostics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Spectral announces 2008 financial results
2. Spectral signs exclusive license agreement to bring sepsis therapeutic to the U.S. market
3. Surface plasmon resonances of metal nanoparticles in array can have narrower spectral widths
4. Spectral announces third quarter 2008 results
5. Spectral to bring anti-sepsis therapy to the U.S. market
6. Spectral announces exclusive distribution agreement in Russia for its EAA(TM) Sepsis Diagnostic Assay
7. Spectral announces continuing support for the combination of EAA(TM) and anti-endotoxin therapeutics
8. Spectral announces presentation of data on improving sepsis patient management with EAA(TM) and Toraymyxin(TM) combination
9. Spectral and Toray expand collaboration to include new geographic territories
10. Spectrals EAA(TM) to be used in Phase III study for a sepsis anti-endotoxin therapy
11. Spectral announces new findings on the effectiveness of EAA(TM)/Toraymyxin(TM) at the 28th International Symposium on Intensive Care and Emergency Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014  Technology Applications International ... that its wholly-owned subsidiary Renuell Int,l, Inc. has signed ... and Space Administration ("NASA") at the Johnson Space Center ... See photos: tapplic.com/houstonphotos/ ... are very pleased to announce our latest, exclusive agreement ...
(Date:9/2/2014)... September 02, 2014 Opertech Bio, ... highly efficient, cost effective approach to sensory evaluation, ... 8,820,265 by the U.S. Patent and Trademark Office, ... , “Opertech’s taste evaluation technology called ... automated high throughput system for rapid characterization of ...
(Date:9/2/2014)... 2, 2014  Xencor, Inc. (NASDAQ: ... monoclonal antibodies for the treatment of autoimmune diseases, ... the appointment of Debra Zack , M.D., ... of Lloyd Rowland , senior vice president, ... "Debra,s expertise in biologics clinical development and ...
(Date:9/2/2014)...  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... targeting specific pathogens that cause serious infections and ... preclinical toxicology study of SYN-004. Per U.S. Food ... was required to move the Company,s lead anti-infective, ... effects of Clostridium difficile (C. difficile), ...
Breaking Biology Technology:Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 2Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 3Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5
... Micromet, Inc. (Nasdaq: ... for the treatment of cancer, inflammation and autoimmune diseases, ... Itin, will present at the Cowen Health Care Conference ... on Tuesday, March 17, 2009. A simultaneous webcast ...
... Company Receives Allowance of Patent Claims in the ... Highlighted in Nature Biotechnology -BRITISH COLUMBIA, Canada, March ... IXSBF; TSX VENTURE: IXS; http://www.ixsbio.com ), a ... monoclonal antibodies based on its Dynamic Cross Linking ...
... Wis., March 6 Mach One Corporation (Pink ... subsidiary, Modular Process Constructors LLC, is changing its ... vision, and announces that it received a contract ... consumer health company. The contract is for a ...
Cached Biology Technology:Micromet to Present at the Cowen Health Care Conference on March 17, 2009 2Micromet to Present at the Cowen Health Care Conference on March 17, 2009 3Micromet to Present at the Cowen Health Care Conference on March 17, 2009 4InNexus Biotechnology Announces New Patents Protecting Novel Cell Penetrating DXL(TM) Antibodies 2InNexus Biotechnology Announces New Patents Protecting Novel Cell Penetrating DXL(TM) Antibodies 3Mach One Subsidiary Modular Process Constructors LLC Changes Name to MPS BioPharm to Better Reflect its Vision 2
(Date:9/2/2014)... with the participation of the University of Granada has ... place in the Iberian Peninsula around the mid Holocene ... dust coming from the Sahara increased. The data came ... Alpine lake in Sierra Nevada (Granada) , This study, ... based on the sedimentation of atmospheric dust from the ...
(Date:9/2/2014)... ideal source of nutrition for infants and it ... evolution and civilizations of human beings. Unlike our ... of bacterial species, including some opportunistic pathogens of ... scientists and physicians. , Indeed, the existence of ... of co-evolutionary and co-adaptive interactions between the microbiome ...
(Date:9/2/2014)... 2014 A study published in the September ... American Academy of Child and Adolescent Psychiatry ... psychiatric diagnosis had an increased risk of developing ... Using data from the nationwide Danish registers, a ... Nielsen, Psychiatry, Aalborg University Hospital, Denmark, studied 48,299children ...
Breaking Biology News(10 mins):Scientists obtain new data on the weather 10,000 years ago from sediments of a lake in Sierra Nevada 2Are human breast milk microbiome 'neutral'? 2Are human breast milk microbiome 'neutral'? 3Risk of diabetes in children and adolescents exposed to antipsychotics 2
... for many people with depression and anxiety disorders, and ... care providers, according to researchers who analyzed the results ... shown to have tremendous benefits for mental health," says ... Program at Southern Methodist University in Dallas. "The more ...
... at Ume University and the Sahlgrenska Academy at the University ... can be found in fish that have been swimming in ... found in higher concentrations in the blood of fish than ... this hormone can lead to infertility in fish. The ...
... neurodegenerative disease spinocerebellar ataxia type 5 (SCA5) damages nerve ... report that the defective protein responsible for the disease ... inside neurons. The study appears in the April 5 ... ( www.jcb.org ). SCA5 results from a faulty ...
Cached Biology News:Mental health providers should prescribe exercise more often for depression, anxiety 2Medicine residues may threaten fish reproduction 2Defective protein is a double hit for ataxia 2
... QRT-PCR Mixes are formulated for use in ... SYBR Green. One-step QRT-PCR mixes offer a ... The pipetting steps are minimised, making the ... ,The 2x ABsolute QRT-PCR Mix is supplied ...
... of environmental and pathophysiological stressful conditions trigger ... known as heat shock proteins (HSPs), more ... The Hsp90 family of proteins in ... beta, Grp94, and Trap-1 (Hsp75). It was ...
... bespoke, cost-effective solutions for complex protein processing and production ... experience to help you develop a solution to your ... , do ... transfer all methodology to your own ...
... The Schleicher & Schuell BioScience Arraying ... dedicated to custom protein and nucleic ... project teams, comprised of R&D, Engineering, ... closely with collaborators every step of ...
Biology Products: